The performance of companies tied to flagship drugs like Viagra presents a nuanced investment scenario . While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced substantial volatility. Investors are now facing the consequences of generic c